Hypoxia Inducible Factors’ Signaling in Pediatric High-Grade Gliomas: Role, Modelization and Innovative Targeted Approaches

The brain tumor microenvironment has recently become a major challenge in all pediatric cancers, but especially in brain tumors like high-grade gliomas. Hypoxia is one of the extrinsic tumor features that interacts with tumor cells, but also with the blood–brain barrier and all normal brain cells. It is the result of a dramatic proliferation and expansion of tumor cells that deprive the tissues of oxygen inflow. However, cancer cells, especially tumor stem cells, can endure extreme hypoxic conditions by rescheduling various genes’ expression involved in cell proliferation, metabolism and angiogenesis and thus, promote tumor expansion, therapeutic resistance and metabolic adaptation. This cellular adaptation implies Hypoxia-Inducible Factors (HIF), namely HIF-1α and HIF-2α. In pediatric high-grade gliomas (pHGGs), several questions remained open on hypoxia-specific role in normal brain during gliomagenesis and pHGG progression, as well how to model it in preclinical studies and how it might be counteracted with targeted therapies. Therefore, this review aims to gather various data about this key extrinsic tumor factor in pHGGs.

[1]  J. Cervós-Navarro,et al.  Selective vulnerability in brain hypoxia. , 1991, Critical reviews in neurobiology.

[2]  J Meixensberger,et al.  Clinical experience with 118 brain tissue oxygen partial pressure catheter probes. , 1998, Neurosurgery.

[3]  Daniel J Brat,et al.  Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. , 2005, Neuro-oncology.

[4]  Daniel J Brat,et al.  'Pseudopalisading' Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis , 2006, Journal of neuropathology and experimental neurology.

[5]  P. Ratcliffe HIF-1 and HIF-2: working alone or together in hypoxia? , 2007, The Journal of clinical investigation.

[6]  J. Pouysségur,et al.  Oxygen, a source of life and stress , 2007, FEBS letters.

[7]  Hui Wang,et al.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.

[8]  L. Denaro,et al.  Hypoxia and HIF1α Repress the Differentiative Effects of BMPs in High‐Grade Glioma , 2009, Stem cells.

[9]  J. Engh,et al.  Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α , 2009, Oncogene.

[10]  R. Deberardinis,et al.  Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. , 2009, Cancer research.

[11]  R. Scienza,et al.  Intratumoral Hypoxic Gradient Drives Stem Cells Distribution and MGMT Expression in Glioblastoma , 2010, Stem cells.

[12]  A. Józkowicz,et al.  HIF-1 and HIF-2 transcription factors — Similar but not identical , 2010, Molecules and cells.

[13]  Alfredo Quiñones-Hinojosa,et al.  Oxygen in stem cell biology: a critical component of the stem cell niche. , 2010, Cell stem cell.

[14]  A. Ashworth,et al.  A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas , 2010, Clinical Cancer Research.

[15]  Peter Canoll,et al.  Magnetic Resonance Imaging Characteristics of Glioblastoma Multiforme: Implications for Understanding Glioma Ontogeny , 2010, Neurosurgery.

[16]  T. MacDonald,et al.  Treatment of high-grade glioma in children and adolescents. , 2011, Neuro-oncology.

[17]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[18]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[19]  N. Potter,et al.  A Prominin-1-Rich Pediatric Glioblastoma: Biologic Behavior Is Determined by Oxygen Tension-Modulated CD133 Expression but Not Accompanied by Underlying Molecular Profiles. , 2012, Translational oncology.

[20]  Chris Jones,et al.  Lactate and Choline Metabolites Detected In Vitro by Nuclear Magnetic Resonance Spectroscopy Are Potential Metabolic Biomarkers for PI3K Inhibition in Pediatric Glioblastoma , 2014, PloS one.

[21]  Kuniaki Saito,et al.  H3F3A K27M mutations in thalamic gliomas from young adult patients. , 2014, Neuro-oncology.

[22]  E. Kleinerman,et al.  Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. , 2014, Anticancer research.

[23]  Stephen Yip,et al.  Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma , 2014, Nature Genetics.

[24]  Michael L Mumert,et al.  Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. , 2014, Neuro-oncology.

[25]  Abdel Kareem Azab,et al.  The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy , 2015, Hypoxia.

[26]  Jill S Barnholtz-Sloan,et al.  Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. , 2015, Neuro-oncology.

[27]  R. Wenger,et al.  Frequently asked questions in hypoxia research , 2015, Hypoxia.

[28]  P. Varlet,et al.  Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes , 2015, Acta Neuropathologica.

[29]  S. Påhlman,et al.  Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, Pharmacology & therapeutics.

[30]  G. Semenza,et al.  Dynamic regulation of stem cell specification and maintenance by hypoxia-inducible factors. , 2016, Molecular aspects of medicine.

[31]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[32]  F. Ducray,et al.  Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort , 2016, Acta Neuropathologica.

[33]  G. Semenza,et al.  Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. , 2016, Trends in cancer.

[34]  P. Ratcliffe,et al.  New horizons in hypoxia signaling pathways , 2017, Experimental cell research.

[35]  E. Letouzé,et al.  Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1a axis inhibition. , 2017, Oncotarget.

[36]  M. D. de Miguel,et al.  Metabolic Reprogramming, Autophagy, and Reactive Oxygen Species Are Necessary for Primordial Germ Cell Reprogramming into Pluripotency , 2017, Oxidative medicine and cellular longevity.

[37]  David R. Jones,et al.  Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme. , 2017, Journal of neurosurgery.

[38]  M. Monje,et al.  Neural Precursor-Derived Pleiotrophin Mediates Subventricular Zone Invasion by Glioma , 2017, Cell.

[39]  S. Vajapeyam,et al.  Correlation of 18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium , 2017, The Journal of Nuclear Medicine.

[40]  Kun Mu,et al.  Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.

[41]  Ji-Yong Um,et al.  Human glioblastoma arises from subventricular zone cells with low-level driver mutations , 2018, Nature.

[42]  David T. W. Jones,et al.  Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial , 2018, Cancer cell.

[43]  M. Monje,et al.  International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma , 2018, Journal of Neuro-Oncology.

[44]  P. Morgan,et al.  Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  I. Sardi,et al.  Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier , 2018, International journal of molecular sciences.

[46]  David T. W. Jones,et al.  Transcriptomic and epigenetic profiling of ‘diffuse midline gliomas, H3 K27M-mutant’ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location , 2018, Acta Neuropathologica Communications.

[47]  G. Semenza,et al.  Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[48]  J. Fangusaro,et al.  REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature , 2017, Oncotarget.

[49]  N. Forsyth,et al.  Reactive Oxygen Species Formation in the Brain at Different Oxygen Levels: The Role of Hypoxia Inducible Factors , 2018, Front. Cell Dev. Biol..

[50]  M. D. Del Bigio,et al.  Characterization of the ventricular-subventricular stem cell niche during human brain development , 2018, Development.

[51]  S. Khatua,et al.  Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Tracy T Batchelor,et al.  Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq , 2018, Science.

[53]  S. Pomeroy,et al.  Brain cancer genomics and epigenomics. , 2018, Handbook of clinical neurology.

[54]  K. Warren Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma , 2018, Front. Oncol..

[55]  Michael C. Rusch,et al.  H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo , 2019, Acta Neuropathologica.

[56]  D. Steindler,et al.  3D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors , 2019, Nature Communications.

[57]  D. Felsher,et al.  MYC regulates the HIF-2α stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells. , 2019, Cancer research.

[58]  M. Jolly,et al.  Acute vs. Chronic vs. Cyclic Hypoxia: Their Differential Dynamics, Molecular Mechanisms, and Effects on Tumor Progression , 2019, Biomolecules.

[59]  Beisi Xu,et al.  Correction to: H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo , 2019, Acta Neuropathologica.

[60]  J. Grill,et al.  Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? , 2019, Journal of Neuro-Oncology.

[61]  B. Lhermitte,et al.  Hypoxic Environment and Paired Hierarchical 3D and 2D Models of Pediatric H3.3-Mutated Gliomas Recreate the Patient Tumor Complexity , 2019, Cancers.

[62]  Shawn M. Gillespie,et al.  Electrical and synaptic integration of glioma into neural circuits , 2019, Nature.

[63]  Richard A. Moore,et al.  Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. , 2019, Cancer research.

[64]  A. Panigrahy,et al.  Quantifying radiation therapy response using apparent diffusion coefficient (ADC) parametric mapping of pediatric diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium , 2019, Journal of Neuro-Oncology.

[65]  Jeff F Dunn,et al.  Partial pressure of oxygen in the human body: a general review. , 2019, American journal of blood research.

[66]  Qiuge Qiao,et al.  Chronic mild hypoxia promotes hippocampal neurogenesis involving Notch1 signaling in epileptic rats , 2019, Brain Research.

[67]  Matthew D. Dun,et al.  Signal Transduction in Diffuse Intrinsic Pontine Glioma , 2019, Proteomics.

[68]  Pieter Wesseling,et al.  cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates , 2019, Brain pathology.

[69]  Rebecca A. Ihrie,et al.  Location-dependent maintenance of intrinsic susceptibility to mTORC1-driven tumorigenesis , 2019, Life Science Alliance.

[70]  Atique U. Ahmed,et al.  Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma , 2019, The Journal of Neuroscience.

[71]  C. Hawkins,et al.  Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas , 2019, Neuro-oncology.

[72]  O. Gevaert,et al.  Whole slide images reflect DNA methylation patterns of human tumors , 2020, npj Genomic Medicine.

[73]  Andreas Holzinger,et al.  Open Data for Differential Network Analysis in Glioma , 2020, International journal of molecular sciences.